Reuters logo
BRIEF-Kite announces positive topline primary results of axicabtagene ciloleucel from first pivotal CAR-T trial
February 28, 2017 / 12:10 PM / 10 months ago

BRIEF-Kite announces positive topline primary results of axicabtagene ciloleucel from first pivotal CAR-T trial

Feb 28 (Reuters) - Kite Pharma Inc

* Kite announces positive topline primary results of axicabtagene ciloleucel from first pivotal CAR-T trial in patients with aggressive non-hodgkin lymphoma

* Says study met primary endpoint of objective response rate

* At a median follow-up of 8.7 months, median overall survival not yet reached

* 41 percent of patients in response and 36 percent in complete response at month 6

* Kite Pharma Inc - plans to submit a marketing authorization application for axicabtagene ciloleucel with European Medicines Agency (EMA) in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below